Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26
- PMID: 27228567
- DOI: 10.1002/hep.28655
Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26
Abstract
A population of stromal cells, myeloid-derived suppressor cells (MDSCs), is present in tumors. Though studies have gradually revealed the protumorigenic functions of MDSCs, the molecular mechanisms guiding MDSC recruitment remain largely elusive. Hypoxia, O2 deprivation, is an important factor in the tumor microenvironment of solid cancers, whose growth often exceeds the growth of functional blood vessels. Here, using hepatocellular carcinoma as the cancer model, we show that hypoxia is an important driver of MDSC recruitment. We observed that MDSCs preferentially infiltrate into hypoxic regions in human hepatocellular carcinoma tissues and that hypoxia-induced MDSC infiltration is dependent on hypoxia-inducible factors. We further found that hypoxia-inducible factors activate the transcription of chemokine (C-C motif) ligand 26 in cancer cells to recruit chemokine (C-X3-C motif) receptor 1-expressing MDSCs to the primary tumor. Knockdown of chemokine (C-C motif) ligand 26 in cancer cells profoundly reduces MDSC recruitment, angiogenesis, and tumor growth. Therapeutically, blockade of chemokine (C-C motif) ligand 26 production in cancer cells by the hypoxia-inducible factor inhibitor digoxin or blockade of chemokine (C-X3-C motif) receptor 1 in MDSCs by chemokine (C-X3-C motif) receptor 1 neutralizing antibody could substantially suppress MDSC recruitment and tumor growth.
Conclusion: This study unprecedentedly reveals a novel molecular mechanism by which cancer cells direct MDSC homing to primary tumor and suggests that targeting MDSC recruitment represents an attractive therapeutic approach against solid cancers. (Hepatology 2016;64:797-813).
© 2016 by the American Association for the Study of Liver Diseases.
Similar articles
-
CCL9/CCR1 induces myeloid‑derived suppressor cell recruitment to the spleen in a murine H22 orthotopic hepatoma model.Oncol Rep. 2019 Jan;41(1):608-618. doi: 10.3892/or.2018.6809. Epub 2018 Oct 18. Oncol Rep. 2019. PMID: 30365155
-
Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis.Hepatology. 2019 Nov;70(5):1564-1581. doi: 10.1002/hep.30676. Epub 2019 Jul 17. Hepatology. 2019. PMID: 31021443 Free PMC article.
-
Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially.Int Immunopharmacol. 2015 Jun;26(2):314-21. doi: 10.1016/j.intimp.2015.04.010. Epub 2015 Apr 16. Int Immunopharmacol. 2015. PMID: 25891236
-
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.Oncoimmunology. 2015 Feb 3;4(1):e954829. doi: 10.4161/21624011.2014.954829. eCollection 2015 Jan. Oncoimmunology. 2015. PMID: 25949858 Free PMC article. Review.
-
Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and age-related chronic inflammatory disorders.Int Immunopharmacol. 2018 Aug;61:231-240. doi: 10.1016/j.intimp.2018.06.005. Epub 2018 Jun 9. Int Immunopharmacol. 2018. PMID: 29894862 Review.
Cited by
-
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China.Chin J Cancer Res. 2022 Aug 30;34(4):353-364. doi: 10.21147/j.issn.1000-9604.2022.04.04. Chin J Cancer Res. 2022. PMID: 36199537 Free PMC article.
-
Hypoxia signaling in cancer: Implications for therapeutic interventions.MedComm (2020). 2023 Jan 23;4(1):e203. doi: 10.1002/mco2.203. eCollection 2023 Feb. MedComm (2020). 2023. PMID: 36703877 Free PMC article. Review.
-
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.J Clin Invest. 2022 May 2;132(9):e156774. doi: 10.1172/JCI156774. J Clin Invest. 2022. PMID: 35499076 Free PMC article.
-
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.Front Immunol. 2022 Jun 10;13:896752. doi: 10.3389/fimmu.2022.896752. eCollection 2022. Front Immunol. 2022. PMID: 35757756 Free PMC article. Review.
-
The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment.Contemp Oncol (Pozn). 2018 Mar;22(1A):7-13. doi: 10.5114/wo.2018.73874. Epub 2018 Mar 5. Contemp Oncol (Pozn). 2018. PMID: 29628788 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous